Study Details
Testing the Drug RAP-219 for People with Refractory Focal Epilepsy
(IRB#: IRB_00181216)
Refractory Focal epilepsy is a disease that affects the brain and causes seizures. This study will test a drug called RAP-219 to treat people with this disease. The study wants to see if the drug will help people with this disease and is safe. People in the study will receive RAP-219, keep a daily diary, complete surveys, and other medical tests. Being in the study requires attending in person visits to the study clinic over 24 weeks. Medical tests will be done during the study to track the health of participants.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 18 to 65 years old
- Diagnosed Refractory Focal Epilepsy
- An implanted responsive neurostimulator (RNS) device with at least one RNS detecting/stimulating electrode placed correctly in a seizure onset zone within the mesial temporal lobe that meets specific criteria
- At least 1 clinical seizure during the 8-week eligibility time period before participation
- In good health other than epilepsy
Exclusion Criteria
- Generalized onset seizures in the past 10 years
- History of status epilepticus while on antiepileptic medication(s) within 2 years before participation
- Pregnant or breastfeeding
- Will not use specific birth control during the study and 6 weeks after the last dose of the study drug
Will I be paid for my time?
Yes
IRB#: IRB_00181216
PI: Angela Peters
Department: NEUROLOGY
Approval Date: 2025-03-05 07:00:00
Study Categories: Brain Health Studies
Specialties: Neurology
I am Interested